News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1206
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => thiết_kế_chưa_có_tên.png
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2024-04-29
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2024-05-11 15:45:25
            [updated_time] => 2024-05-27 09:47:25
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => gentis-thong-bao-moi-hop-dai-hoi-dong-co-dong-thuong-nien-nam-2024
            [title] => Meeting Invitation annual General Meeting of shareholders 2024
            [description] => GENTIS BOD invite Shareholders to take part in the 2024 Annual General Meeting of Shareholders as follows:
            [content] => 




            [content_more] => 
            [meta_title] => Meeting Invitation annual General Meeting of shareholders 2024
            [meta_description] => GENTIS BOD invite Shareholders to take part in the 2024 Annual General Meeting of Shareholders at 9am on May 21, 2024 in Hanoi city
            [meta_keyword] => gentis
            [thumbnail_alt] => 
            [post_id] => 1206
            [category_id] => 4
        )

    [1] => stdClass Object
        (
            [id] => 1115
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 0001.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-08-01
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-08-01 09:39:34
            [updated_time] => 2023-08-22 13:36:50
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => gentis-dong-hanh-cung-hoi-nghi-san-phu-khoa-viet-phap-2023-trong-vai-tro-la-nha-tai-tro-bac
            [title] => GENTIS accompanies the Vietnam-France Congress of Obstetrics and Gynecology 2023 as a silver sponsor
            [description] => The Vietnam-France Conference on Obstetrics and Gynecology 2023 will take place from August 14-15, 2023 in the form of HYBRID: online on the ZOOM platform and directly at Lotte Hotel Hanoi Hall, 54 Lieu Giai, Ba Dinh , Hanoi.
            [content] => 
This is the most important and anticipated event of the year of the National Hospital of Obstetrics and Gynecology. Especially this year, PSTU Hospital in collaboration with the French Society of Obstetrics and Gynecology (CNGOF) organizes many interesting programs such as CME, scientific conferences, international cooperation... The conference is an opportunity for domestic experts. and international students to exchange and share clinical and paraclinical experiences as well as update new knowledge in obstetrics, gynecology, neonatology, assisted reproduction, fetal medicine, pharmacy,...


GENTIS is honored to continue to accompany the Vietnam - France Congress of Obstetrics and Gynecology 2023 and bring meaningful activities on the official conference day (August 15, 2023) such as:
1. GENTIS is honored to provide data for experts in in-depth reports:
- Poor ovarian response - Assoc. Prof. Dr. Ho Sy Hung (Deputy Director of the National Center for HTSS) in the time frame: 11am - 11:30am on August 15.
- The significance of NIPT test in the management of multiple pregnancy - MSc.BS. Nguyen Viet Quang (Director of National Center for Reproductive Medicine - Central Hospital) in the time frame: 16h30 - 16h50 on August 15
Newborn screening for hemoglobin disease - Dr. Tran Thi Chi Mai (Head of Department of Biochemistry, National Children's Hospital - Hanoi Medical University) in the time frame: 16h - 16h20 on August 15
2. GENTIS booth will have genetic testing counseling activities; organize many games, lucky spins with a chance to win 100% gifts for delegates and doctors… in the time frame: 7:30 am - 5:00 pm
 








We cordially invite you and your doctor to attend!
            [content_more] => 
            [meta_title] => 
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1115
            [category_id] => 4
        )

    [2] => stdClass Object
        (
            [id] => 1114
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z4541907198424_abb2a5ef3abd0d700f784f3e8529515e.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-07-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-07-24 10:40:49
            [updated_time] => 2023-08-22 13:54:14
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => geneva-duoc-vinh-danh-top-3-san-pham-dich-vu-chat-luong-toan-cau-2023
            [title] => GenEva was honored with Top 3 global quality products and services in 2023
            [description] => On the morning of July 23, 2023, GENTIS' GenEva high-end prenatal screening test was honored to receive the award of Top 3 GLOBAL QUALITY PRODUCTS - SERVICES 2023.
            [content] => 
Top 3 Global Quality Products and Services 2023 is a prestigious award held annually with the participation of quality products and services of leading companies and units in Vietnam. The goal is to honor good products and services for consumers. To achieve this award, products and services must meet all quality standards and bring value to society.

GenEva premium prenatal screening test was introduced to the market by GENTIS in 2020, bringing top quality products in the field of obstetrics. GenEva combines next-generation sequencing and a proprietary CE-IVD-certified algorithm that is capable of detecting fetal abnormalities even in cases where the amount of free fetal DNA in the mother's blood is at low levels. low (>1.4%). This results in the lowest technical failure rate (0.1%) and eliminates unnecessary invasive testing like other NIPTs.

With 13 years of experience in genetic analysis, GENTIS has analyzed more than 500,000 samples, serving hundreds of thousands of customers each year. As a partner of prestigious medical organizations in Vietnam, GENTIS continuously cooperates with good medical experts and has a team of highly trained, enthusiastic and dedicated consultants. With 2 large-scale and modern laboratories in Hanoi and Ho Chi Minh City, GENTIS is ready to serve customers and partners.
GENTIS is also a unit in Vietnam that meets ISO 15189: 2012 standard on laboratory quality management for NIPT (GenEva). Moreover, the NIPT test at GENTIS also meets the GenQA international standard.
Not only that, GENTIS is transferred with new generation gene sequencing (NGS) technology, the NextSeq 550 machine has high resolution with more than 20 million readings of samples. GENTIS GenEva test results are quite accurate, up to 99.9%. With modern and advanced technology, medical machinery and a team of doctors and experts trained abroad, GENTIS brings the best quality GenEva premium prenatal screening test.
GenEva is a reliable, non-invasive prenatal screening test that is widely accepted and appreciated by experts. With advantages such as safety for pregnant women and fetuses, easy implementation, high accuracy and speed, GenEva will be a useful test for pregnant women.

The award "Top 3 global quality products and services 2023" is a recognition and encouragement for GenEva to continue to improve day by day to best serve the needs of customers and partners. GENTIS is committed to the quality of high-end prenatal screening tests GenEva in particular and genetic analysis tests in general will be further improved.
            [content_more] => 
            [meta_title] => 
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1114
            [category_id] => 4
        )

    [3] => stdClass Object
        (
            [id] => 1113
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => trilv-110.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-07-22
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-07-24 10:14:19
            [updated_time] => 2023-08-22 14:26:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => gentis-bao-cao-tai-hoi-nghi-khoa-hoc-toan-quoc-nam-2023-hoi-y-hoc-gioi-tinh-viet-nam
            [title] => GENTIS reports at the 2023 National Scientific Conference - Vietnam Association of Sex Medicine
            [description] => On the afternoon of July 21, 2023, at the 2023 National Scientific Conference of the Vietnam Association of Sex Medicine with the theme: "VSSM - Sexual health care - multi-dimensional approach", Dr. R&D Director of GENTIS) and Assoc. Prof. Dr. Nguyen Quang (Chairman of the Society of Sex Medicine) had a report at session 4 – PROGRESS IN SEXUAL HEALTH”. The conference took place in 2 days from 21 to 22 July 2023 with 2 parts: Conference program and continuous medical training program.
            [content] => 

The 2023 National Scientific Conference - Vietnam Association of Sex Medicine attracts the participation of more than 300 delegates
National scientific conference in 2023 - Vietnam Association of Sex Medicine with the participation of Assoc. Prof. Dr. Nguyen Quang - President of Vietnam Association of Sex Medicine; Assoc. Prof. Dr. Doan Minh Thuy - Vice President of General Secretary of Vietnam Association of Sex Medicine, Assoc. About 300 delegates are active in the field of sex medicine from major domestic and international hospitals and centers.
At the conference, the rapporteurs in turn presented the latest research results and achievements related to sexual health care for both men and women. After each reporting session, there are speakers, experts and delegates to discuss and exchange experiences in the field of Sex Medicine and Reproductive Health.

Assoc.Prof.Dr. Nguyen Quang (Chairman of the Society of Sex Medicine) and Assoc.
On the side of GENTIS, Dr. Pham Dinh Minh (R&D Director) gave a detailed presentation on the topic "Gene testing in screening & diagnosis of abnormal sex development" before the whole conference. Specifically, Dr. Minh said, sex differentiation starts from the 6th week of pregnancy, starts with the activity of the SRY gene (sex determining region Y), followed by a sequence of activities and mutual regulation of the series. related genes: SOX9, FOXL2, WNT4, RSPO1, DAX1… and extragenomic factors.
Dr. Pham Dinh Minh (R&D Director) reported on the topic "Gene testing in screening & diagnosis of abnormal sex development" before the whole conference.
Disturbances at any stage of the sexual differentiation process in the embryonic period can affect the development of the reproductive organs, development (physical, physiological, mental) menstruation) and reproduction. Therefore, genetic testing is very important to confirm the diagnosis and find the specific cause of the disorder of sex development.
In addition, Dr. Minh also provided to the conference a number of genetic and genetic tests at GENTIS that have been implemented and developed to assist doctors in the diagnosis and assessment of risk factors, thereby helping treatment orientation for each patient such as PGT, NIPT, Karyotype, WES/WGS,... The report of Dr. Pham Dinh Minh received a lot of attention from delegates present at the conference because of its acuteness. Essential and practical in screening and diagnosis of abnormal sex development today.
The 2023 National Scientific Conference - Vietnam Association of Sex Medicine is an opportunity for delegates to connect and cooperate to develop new, in-depth and related research ideas. Once again, GENTIS would like to congratulate the Conference on a great success!
            [content_more] => 
            [meta_title] => GENTIS reports at the 2023 National Scientific Conference - Vietnam Association of Sex Medicine
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1113
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1112
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => thiết_kế_chưa_co_ten_(5).jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-07-20
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-07-20 15:20:07
            [updated_time] => 2023-08-22 14:12:50
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => y-nghia-cua-xet-nghiem-da-hinh-gen-thu-the-fsh-trong-ho-tro-sinh-san
            [title] => Significance of FSH receptor gene polymorphism test in assisted reproduction
            [description] => FSH is a hormone released from the anterior pituitary gland in the brain. FSH stimulates the development of immature oocytes. FSH receptor gene polymorphism testing allows the identification of genetic variants associated with the response to ovarian stimulation.


            [content] => 
1. What is FSH hormone?

FSH (Folicle Stimulating Hormone) is a hormone released from the anterior pituitary gland in the brain. FSH stimulates the development of immature oocytes.
At the beginning of development, the oocyte releases estradiol, which in turn acts on the hypothalamus and pituitary gland to increase the release of GnRH and LH, promoting ovulation. Before ovulation, FSH levels peak, stimulating the ovaries and causing ovulation. Once ovulation has occurred, FSH levels return to baseline or drop slightly below normal.
2. Significance of FSH receptor gene polymorphism test in assisted reproduction
The FSH receptor gene polymorphism test is a test that allows the identification of genetic variants associated with the response to ovarian stimulation. The aim is to produce good quality embryos and increase pregnancy rates in IVF.

 
When ovarian stimulation is performed, depending on the response of the ovaries, the results can be classified into 4 main groups:
• Poor responder according to Bologna criteria: 3 oocytes obtained
• Sub-optimal responder: 4 to 9 oocytes obtained
• Normal responder: 10 to 15 oocytes are obtained
• Hyper-responder: ≥ 15 oocytes obtained
Therefore, the identification and classification of patients is the key to choosing the correct treatment strategy. Currently, poor response to ovarian stimulation is a matter of great concern because this is a very difficult patient group to treat in IVF.
In addition to the problems of ovarian reserve factors such as AFC secondary follicles, AMH hormones, body mass index (BMI), age of the patient, etc., many studies show that FSH receptor gene polymorphisms associated with poor ovarian response.
In Vietnam, FSH receptor gene polymorphism testing is still relatively new. However, in the world, there have been many studies showing that some FSH receptor gene polymorphisms make the amount of drugs that patients need to take more. The four SNPs that have been shown to be associated with poor ovarian response are rs6165, rs6166, rs1394205, rs10835638.
FSH receptor gene polymorphism testing will be a promising and necessary option for individualizing ovarian stimulation and obtaining optimal egg numbers for treatments.

If the patient is a carrier of the FSH receptor gene polymorphism associated with poor ovarian response, the dose of the drug will need to be increased in order to obtain the optimal number of eggs. Like this, the patient will have to stimulate more times, which means an increase in treatment costs. Therefore, we should screen at the beginning to classify the patient into which group.
The FSH receptor gene polymorphism test has been studied and proven to be associated with poor ovarian response, and supports physicians in individualizing and optimizing ovarian stimulation regimens. By performing the FSH receptor gene polymorphism test, the doctor will provide an optimal and personalized ovarian stimulation regimen for each patient, as well as assist in determining the cause of the poor ovarian response. (POR).
It can be seen that performing FSH receptor polymorphism testing is extremely important for women who are about to undergo ovarian stimulation. By performing this test, the doctor will come up with an effective treatment plan, helping infertility cases save time and costs as well as soon "harvest the sweet fruit".
            [content_more] => 
            [meta_title] => 
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1112
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1110
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 2_(1).jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-07-19
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-07-19 13:35:16
            [updated_time] => 2024-06-19 14:40:12
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => xet-nghiem-nipt-cua-gentis-tu-hao-dat-chat-luong-ngoai-kiem-chuan-quoc-te-genqa
            [title] => GENTIS's NIPT test is proud to meet the international quality standard GenQA
            [description] => GENTIS is proud to be one of the units with leading modern laboratory systems and machines imported from Europe, America,..., always meeting domestic and foreign quality standards. In particular, GENTIS's NIPT test is proud to meet ISO 15189:2012 and GenQA international quality standards.

            [content] => 
 
(NIPT - Non - Invasive Prenatal Test) is a non-invasive prenatal screening test that helps to detect syndromes related to chromosomal abnormalities in the fetus through maternal blood such as Down syndrome, Edwards, Patau, any usually the number of sex chromosomes X, Y, mutations, deletion/repetition, etc. ensure safety and accuracy over 99%.
External control is a mandatory program that laboratories must participate in to evaluate the quality of test results. This is not only to meet the requirements of state management agencies and certification organizations, but also for the laboratory to confirm the quality of test results with customers.
GENTIS is one of the few specialized testing centers in Vietnam that owns and masters America's new generation of gene sequencing technology. Therefore, the NIPT tests at GENTIS have faster, more accurate and more specific results for the Vietnamese population.

ESPECIALY, GENTIS international laboratory system always surpasses many strict quality standards both at home and abroad:
• Obtained ISO 15189:2012 certification for the quality and capacity of medical laboratories.
• Reaching the quality of the UK's GenQA international standard.
In particular, more than 100 major partners and 700 long-term customers of GENTIS are major hospitals in Vietnam such as: Central Obstetrics and Gynecology Hospital, Hanoi Obstetrics and Gynecology Hospital, Hanoi Cancer Hospital, Bach Mai Hospital, etc. Not only that, GENTIS is also a research partner with prestigious medical units such as Hanoi Hospital of Andrology and Fertility, National Hospital of Obstetrics and Gynecology, Military Institute of Clinical Embryology, Hung Vuong Hospital, etc. to publish many quality scientific articles in prestigious journals.
Thanks to pioneering technology and owning a system of specialized laboratories for genetics, GENTIS's NIPT test affirms its quality, reliability and high accuracy of up to 99.9%. With 13 years of operation in the market, GENTIS International Testing Center is a reliable address providing prenatal screening services that many pregnant women trust, choose to experience and are satisfied with the results.
GENTIS's NIPT test meets ISO 15189:2012 and GenQA external control not only demonstrates the test's capacity, quality, and test value, but also once again affirms the accuracy and reliability of the tests. customer service test results. With the seriousness on the journey of testing quality management, people across the country can be completely assured of GENTIS's NIPT test results.
            [content_more] => 
            [meta_title] => GENTIS's NIPT test is proud to meet the international quality standard GenQA
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1110
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1109
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 1-compressed_(3).jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-07-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-07-13 15:51:22
            [updated_time] => 2023-08-22 14:48:34
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => gentis-tiep-doan-chuyen-gia-danh-gia-giam-sat-va-mo-rong-tieu-chuan-iso-151892012
            [title] => GENTIS receives a delegation of Auditors to monitor and expand ISO 15189:2012
            [description] => On July 10 - 12, 2023, GENTIS was honored to welcome a delegation of Auditors from the Office of Quality Accreditation (BoA) to conduct the NIPT test monitoring assessment and the criteria to expand the package. NIPT tests (such as PGT-A, Thalassemia, ...) according to ISO 15189:2012 for GENTIS International Laboratories. This event marked the development of the capacity and quality assurance management system in GENTIS testing operations.

            [content] => 

The meeting had the presence of Ms. Nguyen Hong Nhung - Quality Assessor, Quality Accreditation Office as Head of the Evaluation Team and Mr. Duong Quoc Chinh - Hematology Technical Evaluation Specialist, Institute of Hematology Transfusion. Central Blood and GENTIS leadership representatives, all staff of GENTIS international laboratory and ISO department of GENTIS.
According to the assessment program, from July 10 to 12, 2023, the assessment team worked directly at the office and the GENTIS International Laboratory to conduct surveillance assessment of NIPT testing, the indicators. extended to NIPT test packages according to ISO 15189:2012.

The audit team examined the records related to the application and development of the quality management system according to the ISO 15189:2012 certificate issued for the NIPT test. At the same time, extensive evaluation for NIPT test packages meets ISO 15189:2012 standards. As follows:
• Management requirements (4.1 – 4.15)
• Technical requirements (5.1 – 5.10)
• Management requirements (4.3; 4.9; 4.13)
• Technical requirements (5.1 – 5.10)
• Observing test indicators
• Observe sampling, transport and receiving samples.
• Observe the result reporting system
The meeting took place in an atmosphere of urgency and seriousness. At the end of the meeting, Ms. Nguyen Hong Nhung - Head of the assessment team made some comments as follows: GENTIS complies well with the standard requirements of the system.
Through the evaluation of NIPT testing supervision and the expanded criteria for NIPT test packages according to ISO 15189:2012, GENTIS has demonstrated to the expert team its ability to fully satisfy in quantity and quality. quality standards including facilities, personnel, equipment, quality management system in accordance with the regulations of the Laboratory.
The evaluation and supervision of NIPT testing and the expanded criteria for NIPT test packages according to ISO 15189:2012 standard in order to improve the capacity of GENTIS International Laboratories, ensure better service quality for customers. The final conclusion of the surveillance and quota expansion was that the GENTIS International Laboratory met the requirements for maintaining accreditation according to ISO 15189:2012.

On behalf of GENTIS Company, Mr. Nguyen Quang Vinh - Director of the Testing Center expressed his thanks and received the comments of the evaluation team so that GENTIS could perfect, as well as further develop the system, to improve the quality of the work. working in the areas of operation of the GENTIS International Laboratory.
            [content_more] => 
            [meta_title] => GENTIS receives a delegation of Auditors to monitor and expand ISO 15189:2012
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1109
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1108
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => lop-hoc-tien-san-bv-lac-viet-2.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2023-07-11
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2023-07-11 13:11:21
            [updated_time] => 2023-08-22 14:53:07
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => gentis-dong-hanh-cung-lop-hoc-tien-san-thang-7-tai-bv-huu-nghi-lac-viet
            [title] => GENTIS accompanies the July Prenatal Class at Lac Viet Friendship Hospital
            [description] => On the morning of July 9, GENTIS and Lac Viet Friendship Hospital jointly organized an extremely meaningful July antenatal class with the theme: "Common problems of postpartum women - Recognizing and handling ". The class has brought pregnant mothers useful and practical knowledge after giving birth.

            [content] => 
As a topic of interest to many pregnant women, the July antenatal class at Lac Viet Friendship Hospital attracted more than 50 parents in the area to participate and experience and accumulate knowledge. Lecturer at the class is Master of Resident Doctor Nguyen Thi Hang - Department of Obstetrics and Gynecology, Lac Viet Friendship Hospital. GENTIS is honored to have the participation of Ms. Le Thi Hong Nhung - Product Management Department.

Here, pregnant mothers were shared by Dr. Hang about safe motherhood, common problems after giving birth, postpartum care, etc. The program was lively and received very positive feedback from parents.
The July prenatal class at Lac Viet Friendship Hospital becomes a place to share worries during pregnancy, childbirth, postpartum and provide a lot of knowledge for pregnant mothers. The class is not only for pregnant women but also attracts many fathers, grandmothers and grandmothers to participate because taking care of a new born baby is the task of many people. Through the antenatal class in July, not only the mother but also the father is equipped with basic knowledge of postpartum knowledge.
Not only that, parents also listened to Ms. Le Thi Hong Nhung - Product Management Department of GENTIS Company share about NBS testing. In Vietnam, the NBS program with regional projects has been implemented since 1998. In 2015, NBS was deployed nationwide with 3 diseases: congenital hypothyroidism, congenital adrenal hyperplasia and G6PD enzyme deficiency. In recent years, NBS has expanded to more groups of diseases such as congenital metabolic disorders, abnormal red blood cells, galactosemia, phenylketouria...

This is an important test to help detect congenital pathology early for timely treatment, to avoid disease progression and difficulty in treatment, as well as to reduce costs for later treatment sessions or become a burden for families and friends. society.
In addition, expectant mothers are also asked questions throughout the process from pregnancy, delivery to the postpartum period. In particular, pregnant mothers who register for the Maternity Service Package when participating in the July antenatal class at Lac Viet Friendship Hospital will receive a FREE GENTIS package of NBS heel blood collection to screen for 5 diseases for their baby.
GENTIS is always proud to be a pioneer in the field of genetic analysis; We are always at the forefront of technological innovation with the desire to bring safe and scientific test packages. Hopefully in the future, GENTIS will always receive the trust and support from everyone.
            [content_more] => 
            [meta_title] => GENTIS accompanies the July Prenatal Class at Lac Viet Friendship Hospital
            [meta_description] => 
            [meta_keyword] => 
            [thumbnail_alt] => 
            [post_id] => 1108
            [category_id] => 4
        )

)